<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T04:46:21Z</responseDate>
  <request identifier="oai:figshare.com:article/34026784" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34026784</identifier>
        <datestamp>2026-09-29T17:37:50Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_122</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Target trial emulation study design.&lt;/p&gt;</dc:title>
          <dc:creator>Po-Huang Chen (8374326)</dc:creator>
          <dc:creator>Ming-Shen Dai (835570)</dc:creator>
          <dc:creator>Mao-Hsuan Huang (17475456)</dc:creator>
          <dc:creator>Hsin-Yu Chen (2165956)</dc:creator>
          <dc:creator>Li-Ting Kao (409065)</dc:creator>
          <dc:creator>Tina Yi-Jin Hsieh (22887737)</dc:creator>
          <dc:creator>Hong-Jie Jhou (9376258)</dc:creator>
          <dc:creator>Cho-Hao Lee (4114723)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Mental Health</dc:subject>
          <dc:subject>showed null associations</dc:subject>
          <dc:subject>related adverse events</dc:subject>
          <dc:subject>propensity score matching</dc:subject>
          <dc:subject>prior 365 days</dc:subject>
          <dc:subject>preceding 90 days</dc:subject>
          <dc:subject>level pattern matched</dc:subject>
          <dc:subject>groups may differ</dc:subject>
          <dc:subject>everyday functional ability</dc:subject>
          <dc:subject>enhancing antitumor immunity</dc:subject>
          <dc:subject>cd8 +&amp;# 8201</dc:subject>
          <dc:subject>cancer genome atlas</dc:subject>
          <dc:subject>20 cancer types</dc:subject>
          <dc:subject>first ici administration</dc:subject>
          <dc:subject>008 ), driven</dc:subject>
          <dc:subject>cannot localize slc6a4</dc:subject>
          <dc:subject>272 tumor samples</dc:subject>
          <dc:subject>year overall survival</dc:subject>
          <dc:subject>target trial emulation</dc:subject>
          <dc:subject>bzd prescription overlapping</dc:subject>
          <dc:subject>&gt;- value 2</dc:subject>
          <dc:subject>134 matched patients</dc:subject>
          <dc:subject>slc6a4 expression related</dc:subject>
          <dc:subject>immune checkpoint blockade</dc:subject>
          <dc:subject>users among patients</dc:subject>
          <dc:subject>hr range 0</dc:subject>
          <dc:subject>target trial</dc:subject>
          <dc:subject>slc6a4 expression</dc:subject>
          <dc:subject>immune checkpoint</dc:subject>
          <dc:subject>tumor immune</dc:subject>
          <dc:subject>ssri users</dc:subject>
          <dc:subject>among 3</dc:subject>
          <dc:subject>solid tumor</dc:subject>
          <dc:subject>composite immune</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>versus 34</dc:subject>
          <dc:subject>thyroid dysfunction</dc:subject>
          <dc:subject>starting within</dc:subject>
          <dc:subject>ssri use</dc:subject>
          <dc:subject>ssri repurposing</dc:subject>
          <dc:subject>ssri group</dc:subject>
          <dc:subject>solid tumors</dc:subject>
          <dc:subject>serotonin transporter</dc:subject>
          <dc:subject>residual confounding</dc:subject>
          <dc:subject>psychiatric comorbidity</dc:subject>
          <dc:subject>primary outcome</dc:subject>
          <dc:subject>performance status</dc:subject>
          <dc:description>&lt;p&gt;Schematic diagram of the target trial emulation framework comparing SSRI with benzodiazepine use among patients with a solid tumor and depression or anxiety who were receiving immune checkpoint inhibitors. The study timeline is divided into baseline (365 days before the index date), the index date (first ICI administration, time zero), and follow-up (days 30 to 730 after the index date, beginning at the prespecified 30-day landmark). Abbreviations: BZD, benzodiazepine; ICI, immune checkpoint inhibitor; SSRI, selective serotonin reuptake inhibitor.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T18:01:32Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pmed.1005262.g001</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Target_trial_emulation_study_design_p_/34026784</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
